Estrogen induces androgen-repressed SOX4 expression to promote progression of prostate cancer cells

Prostate

Volumn 75, Issue 13, 2015, Pages 1363-1375

  Yang, Muyi ^a   Wang, Jing ^b   Wang, Lin ^a,c   Shen, Chengwu ^d   Su, Bo ^a   Qi, Mei ^a   Hu, Jing ^a   Gao, Wei ^e   Tan, Weiwei ^a   Han, Bo ^a,f  

^a SHANDONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b Fourth People's Hospital of Jinan   (China)

^c SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG FIRST MEDICAL UNIVERSITY   (China)

^d SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

^e JINAN CENTRAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

^f SHANDONG UNIVERSITY   (China)

Author keywords

androgen receptor; estrogen receptor beta; overexpression; prostate cancer; SOX4 Gene

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; ANDROSTANOLONE; BICALUTAMIDE; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR BETA; FLUTAMIDE; MESSENGER RNA; TRANSCRIPTION FACTOR SOX4; SOX4 PROTEIN, HUMAN; TRANSCRIPTION FACTOR SOX;

ANDROGEN DEPRIVATION THERAPY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CARCINOGENESIS; CASTRATION RESISTANT PROSTATE CANCER; CELL FUNCTION; CELL INVASION; CELL INVASION ASSAY; CELL STIMULATION; CELLULAR DISTRIBUTION; CHROMATIN IMMUNOPRECIPITATION; COHORT ANALYSIS; COMPLEX FORMATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; GENE SILENCING; HORMONAL REGULATION; HORMONE ACTION; HORMONE DEPENDENT PROSTATE CANCER; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE TEST; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; IN VITRO STUDY; LUCIFERASE ASSAY; MAJOR CLINICAL STUDY; MALE; MIGRATION INHIBITION; MTS ASSAY; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; PROSTATE CANCER CELL LINE; PROSTATECTOMY; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; REAL TIME POLYMERASE CHAIN REACTION; RECEPTOR BINDING; TRANSCRIPTION REGULATION; TRANSURETHRAL RESECTION; UPREGULATION; WESTERN BLOTTING; WOUND HEALING; CELL MOTION; CELL PROLIFERATION; DISEASE COURSE; DRUG EFFECTS; GENE EXPRESSION REGULATION; METABOLISM; PATHOLOGY; PROSTATE; PROSTATE TUMOR; TUMOR CELL LINE; TUMOR INVASION;

CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DISEASE PROGRESSION; ESTRADIOL; ESTROGEN RECEPTOR BETA; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; NEOPLASM INVASIVENESS; PROSTATE; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; SOXC TRANSCRIPTION FACTORS; UP-REGULATION;

EID: 84939264657     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.23017     Document Type: Article

References (41)

1. Siegel R, Naishadham D, Jemal A,. Cancer statistics, 2012. CA Cancer J Clin 2012; 62 (1): 10-29.
2. Zong Y, Goldstein AS,. Adaptation or selection-mechanisms of castration-resistant prostate cancer. Nat Rev Urol 2013; 10 (2): 90-98.
3. Feldman BJ, Feldman D,. The development of androgen-independent prostate cancer. Nat Rev Cancer 2001; 1 (1): 34-45.
4. Scher HI, Sawyers CL,. Biology of progressive, castration-resistant prostate cancer: Directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol 2005; 23 (32): 8253-8261.
5. Isaacs JT, Coffey DS,. Adaptation versus selection as the mechanism responsible for the relapse of prostatic cancer to androgen ablation therapy as studied in the Dunning R-3327-H adenocarcinoma. Cancer Res 1981; 41 (12 Pt 1): 5070-5075.
6. Ellem SJ, Risbridger GP,. Treating prostate cancer: A rationale for targeting local oestrogens. Nat Rev Cancer 2007; 7 (8): 621-627.
7. Ricke WA, McPherson SJ, Bianco JJ, Cunha GR, Wang Y, Risbridger GP,. Prostatic hormonal carcinogenesis is mediated by in situ estrogen production and estrogen receptor alpha signaling. FASEB J 2008; 22 (5): 1512-1520.
8. Heldring N, Pike A, Andersson S, Matthews J, Cheng G, Hartman J, Tujague M, Strom A, Treuter E, Warner M, Gustafsson JA,. Estrogen receptors: How do they signal and what are their targets. Physiol Rev 2007; 87 (3): 905-931.
9. Bonkhoff H, Berges R,. The evolving role of oestrogens and their receptors in the development and progression of prostate cancer. Eur Urol 2009; 55 (3): 533-542.
10. Dey P, Jonsson P, Hartman J, Williams C, Strom A, Gustafsson JA,. Estrogen receptors beta1 and beta2 have opposing roles in regulating proliferation and bone metastasis genes in the prostate cancer cell line PC3. Mol Endocrinol 2012; 26 (12): 1991-2003.
11. McPherson SJ, Hussain S, Balanathan P, Hedwards SL, Niranjan B, Grant M, Chandrasiri UP, Toivanen R, Wang Y, Taylor RA, Risbridger GP,. Estrogen receptor-beta activated apoptosis in benign hyperplasia and cancer of the prostate is androgen independent and TNFalpha mediated. Proc Natl Acad Sci USA 2010; 107 (7): 3123-3128.
12. Zellweger T, Sturm S, Rey S, Zlobec I, Gsponer JR, Rentsch CA, Terracciano LM, Bachmann A, Bubendorf L, Ruiz C,. Estrogen receptor beta expression and androgen receptor phosphorylation correlate with a poor clinical outcome in hormone-naive prostate cancer and are elevated in castration-resistant disease. Endocr Relat Cancer 2013; 20 (3): 403-413.
13. Bouchal J, Santer FR, Hoschele PP, Tomastikova E, Neuwirt H, Culig Z,. Transcriptional coactivators p300 and CBP stimulate estrogen receptor-beta signaling and regulate cellular events in prostate cancer. Prostate 2011; 71 (4): 431-437.
14. Vervoort SJ, van Boxtel R, Coffer PJ,. The role of SRY-related HMG box transcription factor 4 (SOX4) in tumorigenesis and metastasis: Friend or foe?. Oncogene 2013; 32 (29): 3397-3409.
15. Liu P, Ramachandran S, Ali Seyed M, Scharer CD, Laycock N, Dalton WB, Williams H, Karanam S, Datta MW, Jaye DL, Moreno CS,. Sex-determining region Y box 4 is a transforming oncogene in human prostate cancer cells. Cancer Res 2006; 66 (8): 4011-4019.
16. Wang L, Zhang J, Yang X, Chang YW, Qi M, Zhou Z, Zhang J, Han B,. SOX4 is associated with poor prognosis in prostate cancer and promotes epithelial-mesenchymal transition in vitro. Prostate Cancer Prostatic Dis 2013; 16 (4): 301-307.
17. Medina PP, Castillo SD, Blanco S, Sanz-Garcia M, Largo C, Alvarez S, Yokota J, Gonzalez-Neira A, Benitez J, Clevers HC, Cigudosa JC, Lazo PA, Sanchez-Cespedes M,. The SRY-HMG box gene, SOX4, is a target of gene amplification at chromosome 6p in lung cancer. Hum Mol Genet 2009; 18 (7): 1343-1352.
18. Moreno CS,. The Sex-determining region Y-box 4 and homeobox C6 transcriptional networks in prostate cancer progression: Crosstalk with the Wnt, Notch, and PI3K pathways. Am J Pathol 2010; 176 (2): 518-527.
19. Zhang J, Shen C, Wang L, Ma Q, Xia P, Qi M, Yang M, Han B,. Metformin inhibits epithelial-mesenchymal transition in prostate cancer cells: Involvement of the tumor suppressor miR30a and its target gene SOX4. Biochem Biophys Res Commun 2014; 452 (3): 746-752.
20. Kang M, Li Y, Liu W, Wang R, Tang A, Hao H, Liu Z, Ou H,. MiR-129-2 suppresses proliferation and migration of esophageal carcinoma cells through downregulation of SOX4 expression. Int J Mol Med 2013; 32 (1): 51-58.
21. Zhou X, Li L, Su J, Zhang G,. Decreased miR-204 in H. pylori-associated gastric cancer promotes cancer cell proliferation and invasion by targeting SOX4. PLoS One 2014; 9 (7): e101457.
22. Han B, Mehra R, Lonigro RJ, Wang L, Suleman K, Menon A, Palanisamy N, Tomlins SA, Chinnaiyan AM, Shah RB,. Fluorescence in situ hybridization study shows association of PTEN deletion with ERG rearrangement during prostate cancer progression. Mod Pathol 2009; 22 (8): 1083-1093.
23. Hobisch A, Hittmair A, Daxenbichler G, Wille S, Radmayr C, Hobisch-Hagen P, Bartsch G, Klocker H, Culig Z,. Metastatic lesions from prostate cancer do not express oestrogen and progesterone receptors. J Pathol 1997; 182 (3): 356-361.
24. Wang L, Song G, Chang X, Tan W, Pan J, Zhu X, Liu Z, Qi M, Yu J, Han B,. The role of TXNDC5 in castration-resistant prostate cancer-involvement of androgen receptor signaling pathway. Oncogene 2014.
25. Han B, Mehra R, Dhanasekaran SM, Yu J, Menon A, Lonigro RJ, Wang X, Gong Y, Wang L, Shankar S, Laxman B, Shah RB, Varambally S, Palanisamy N, Tomlins SA, Kumar-Sinha C, Chinnaiyan AM,. A fluorescence in situ hybridization screen for E26 transformation-specific aberrations: Identification of DDX5-ETV4 fusion protein in prostate cancer. Cancer Res 2008; 68 (18): 7629-7637.
26. Ding Y, Wang X, Xu A, Xu X, Tian K, Young CY, Yuan H,. Associations of saposin C, Src, and androgen receptor upregulate the expression and function of androgen receptor in human prostate cancer cells. J Cell Biochem 2011; 112 (3): 818-828.
27. Wang W, Zhang J, Zhan X, Lin T, Yang M, Hu J, Han B, Hu S,. SOX4 is associated with poor prognosis in cholangiocarcinoma. Biochem Biophys Res Commun 2014; 452 (3): 614-621.
28. Singh PB, Matanhelia SS, Martin FL,. A potential paradox in prostate adenocarcinoma progression: Oestrogen as the initiating driver. Eur J Cancer 2008; 44 (7): 928-936.
29. Takahashi Y, Perkins SN, Hursting SD, Wang TT,. 17beta-Estradiol differentially regulates androgen-responsive genes through estrogen receptor-beta- and extracellular-signal regulated kinase-dependent pathways in LNCaP human prostate cancer cells. Mol Carcinog 2007; 46 (2): 117-129.
30. Sampson N, Neuwirt H, Puhr M, Klocker H, Eder IE,. In vitro model systems to study androgen receptor signaling in prostate cancer. Endocr Relat Cancer 2013; 20 (2): R49-R64.
31. Kregel S, Kiriluk KJ, Rosen AM, Cai Y, Reyes EE, Otto KB, Tom W, Paner GP, Szmulewitz RZ, Vander Griend,. Sox2 is an androgen receptor-repressed gene that promotes castration-resistant prostate cancer. PLoS One 2013; 8 (1): e53701.
32. Yang L, Ravindranathan P, Ramanan M, Kapur P, Hammes SR, Hsieh JT, Raj GV,. Central role for PELP1 in nonandrogenic activation of the androgen receptor in prostate cancer. Mol Endocrinol 2012; 26 (4): 550-561.
33. Hunt SM, Clarke CL,. Expression and hormonal regulation of the Sox4 gene in mouse female reproductive tissues. Biol Reprod 1999; 61 (2): 476-481.
34. Lowry WE, Blanpain C, Nowak JA, Guasch G, Lewis L, Fuchs E,. Defining the impact of beta-catenin/Tcf transactivation on epithelial stem cells. Genes Dev 2005; 19 (13): 1596-1611.
35. Tavazoie SF, Alarcon C, Oskarsson T, Padua D, Wang Q, Bos PD, Gerald WL, Massague J,. Endogenous human microRNAs that suppress breast cancer metastasis. Nature 2008; 451 (7175): 147-152.
36. Celhay O, Yacoub M, Irani J, Dore B, Cussenot O, Fromont G,. Expression of estrogen related proteins in hormone refractory prostate cancer: Association with tumor progression. J Urol 2010; 184 (5): 2172-2178.
37. Christoforou P, Christopoulos PF, Koutsilieris M,. The role of estrogen receptor beta in prostate Cancer. Mol Med 2014.
38. Prins GS, Korach KS,. The role of estrogens and estrogen receptors in normal prostate growth and disease. Steroids 2008; 73 (3): 233-244.
39. Wang Q, Li W, Zhang Y, Yuan X, Xu K, Yu J, Chen Z, Beroukhim R, Wang H, Lupien M, Wu T, Regan MM, Meyer CA, Carroll JS, Manrai AK, Janne OA, Balk SP, Mehra R, Han B, Chinnaiyan AM, Rubin MA, True L, Fiorentino M, Fiore C, Loda M, Kantoff PW, Liu XS, Brown M,. Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell 2009; 138 (2): 245-256.
40. Jin HJ, Kim J, Yu J,. Androgen receptor genomic regulation. Transl Androl Urol 2013; 2 (3): 157-177.
41. Horvath LG, Henshall SM, Lee CS, Head DR, Quinn DI, Makela S, Delprado W, Golovsky D, Brenner PC, O'Neill G, Kooner R, Stricker PD, Grygiel JJ, Gustafsson JA, Sutherland RL,. Frequent loss of estrogen receptor-beta expression in prostate cancer. Cancer Res 2001; 61 (14): 5331-5335.